CORDIS
EU research results

CORDIS

English EN

New therapies for uveal melanoma

Objective

Uveal melanoma (UM) is a rare intraocular tumour with an incidence of 5 cases per million individuals per year. Up to 50% of UM patients develop metastases, most often in the liver, and these are invariably fatal. Despite new discoveries in the genetic and molecular background of the primary tumour, little is known about the metastatic disease; furthermore, there is no therapy to either prevent or treat UM metastases. In UM Cure 2020, we aim to identify and validate at the preclinical level novel therapeutic approaches for the treatment of UM metastases. For this purpose, the consortium brings together the major experts of UM in both patient care and basic/translational/clinical research, as well as patient representatives. An ambitious multidisciplinary approach is proposed to move from patient tissue characterisation to preclinical evaluation of single or combinations of drugs. This approach includes the characterisation of the genetic landscape of metastatic UM and its microenvironment, proteomic studies to address signal pathway deregulation and establishment of novel relevant in vitro and in vivo UM models. We also aim to validate accurate surrogate endpoint biomarkers to evaluate therapies and detect metastases as early as possible. Underpinning this will be the UM Cure 2020 virtual biobank registry, linking existing biobanks into a harmonised network, which will prospectively collect primary and metastatic UM samples. Together, our approach will lead to the identification of new therapies, allowing the initiation of UM-dedicated clinical trials sponsored by academia or pharma. Dissemination of results will include the building of a patient network across the countries as part of the consortium as well as a dedicated UM patient and caregiver’s data portal as part of the UM Cure 2020 website, in order to increase patient information and disease awareness.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUT CURIE

Address

Rue D'Ulm 26
75231 Paris

France

Activity type

Research Organisations

EU Contribution

€ 1 659 000

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 1 021 540

UNIVERSITEIT LEIDEN

Netherlands

EU Contribution

€ 434 376,25

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 358 604

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 993 956

UNIWERSYTET JAGIELLONSKI

Poland

EU Contribution

€ 213 792,50

KARLSRUHER INSTITUT FUER TECHNOLOGIE

Germany

EU Contribution

€ 10 000

FUNDACAO D. ANNA SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD

Portugal

EU Contribution

€ 248 750

MELANOMA PATIENT NETWORK EUROPE

Sweden

EU Contribution

€ 61 250

PAMGENE INTERNATIONAL BV

Netherlands

EU Contribution

€ 469 625

PEP THERAPY

France

EU Contribution

€ 191 500

SEEDING SCIENCE

France

EU Contribution

€ 216 875

UNIVERSITA DEGLI STUDI DI TRENTO

Italy

EU Contribution

€ 304 187,50

Project information

Grant agreement ID: 667787

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 7 971 101,25

  • EU contribution

    € 6 183 456,25

Coordinated by:

INSTITUT CURIE

France